Prevalence and Patterns of Non‐Medical Gabapentinoid Use in a General Population Sample: Findings From the Australian National Drug Strategy Household Survey
Drug and Alcohol Review · 2026-05 · 45 (4)
DOI: 10.1111/dar.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Review, online erschienen am 27.04.2026. Verfasst von Amy G McNeilage und 4 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Gabapentin, Analgesics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pain Foundation Ltd, National Health and Medical Research Council.
Abstract (Originalsprache)
Introduction
Gabapentinoid prescribing and related harms are increasing internationally, yet population‐level evidence on non‐medical use in Australia is lacking. This study estimated the prevalence and correlates of past‐year non‐medical gabapentinoid use and examined temporal trends.
Methods
Data were pooled from the 2016, 2019 and 2022–2023 National Drug Strategy Household Surveys ( N = 67,103). Analyses applied person‐level survey weights and accounted for the complex design. Weighted descriptive, trend and multinomial logistic regression analyses were conducted, with covariates prespecified using a directed acyclic graph.
Results
Past‐year non‐medical gabapentinoid use among Australians aged ≥ 14 years increased from 0.06% in 2016 to 0.15% in 2022–2023 (Adjusted Wald F = 5.86, p = 0.016; OR = 1.57, 95% CI 1.09, 2.25). Among those reporting any non‐medical pain medication use, the proportion involving gabapentinoids rose from 1.7% to 9.3%. Individuals reporting non‐medical gabapentinoid use were more likely to report chronic pain (adjusted relative risk ratio [aRRR] = 5.66, 95% CI 3.18, 10.08), high psychological distress (aRRR = 4.26, 95% CI 2.31, 7.84), and socioeconomic disadvantage (aaRRR = 3.45, 95% CI 1.91, 6.27), compared to those reporting no non‐medical pain medication use. Most (71%) also reported non‐medical opioid use. Discussion and Conclusions Although non‐medical gabapentinoid use remains uncommon in Australia, its prevalence is increasing. Findings are consistent with non‐medical use occurring in the context of unmet pain and mental health needs rather than predominantly recreational use. Enhanced prescriber awareness, harm reduction initiatives, and expanded access to non‐pharmacological pain and mental health care are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia.
- Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
- School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
ORCID-Profile: Amy G McNeilage, Ting Xia
Förderung
- Pain Foundation Ltd
- National Health and Medical Research Council
Zitieren
APA
McNeilage, A. G., Xia, T., Murnion, B., Ashton-James, C. E., & Nielsen, S. (2026). Prevalence and Patterns of Non‐Medical Gabapentinoid Use in a General Population Sample: Findings From the Australian National Drug Strategy Household Survey. Drug and Alcohol Review, 45(4). https://doi.org/10.1111/dar.70165
Vancouver
McNeilage AG, Xia T, Murnion B, Ashton-James CE, Nielsen S. Prevalence and Patterns of Non‐Medical Gabapentinoid Use in a General Population Sample: Findings From the Australian National Drug Strategy Household Survey. Drug and Alcohol Review. 2026;45(4). doi:10.1111/dar.70165
BibTeX
@article{McNeilage2026,
author = {McNeilage, Amy G and Xia, Ting and Murnion, Bridin and Ashton-James, Claire E and Nielsen, Suzanne},
title = {Prevalence and Patterns of Non‐Medical Gabapentinoid Use in a General Population Sample: Findings From the Australian National Drug Strategy Household Survey},
journal = {Drug and Alcohol Review},
year = {2026},
volume = {45},
number = {4},
doi = {10.1111/dar.70165}
}
EUVIMED